Strides Pharma Science Limited's Board of Directors approved significant changes to its composition and senior leadership, effective June 1, 2026, following a meeting held on May 18, 2026. These decisions, based on recommendations from the Nomination and Remuneration Committee, are part of the company's comprehensive succession planning framework aimed at strengthening executive management representation and promoting internal talent. The board meeting commenced at 12:30 hrs IST and concluded at 14:15 hrs IST.

Key Board and Management Changes

The following changes to the Board of Directors and senior leadership have been approved:

Elevation of Ramaraju PVS as Executive Director

Venkata Seetharama Raju Pakalapati, widely known as Ramaraju PVS or Ram, has been appointed as a whole-time director designated as Executive Director for a period of three years with effect from June 1, 2026, subject to shareholders' approval. Ramaraju has been part of the Strides group for over 18 years and brings more than two decades of experience in the pharmaceutical and healthcare industry. His leadership approach is characterised by strategic foresight, collaborative synergy, and an unwavering commitment to excellence. As Executive Director, he will be responsible for overseeing global technical operations and the strategic management of critical functions including Manufacturing, Supply Chain, Procurement, and new digital initiatives. Consequent to this elevation, Ramaraju is designated as Key Managerial Personnel (KMP) effective June 1, 2026, and will cease as Senior Management Personnel (SMP) with effect from end of business hours of May 31, 2026.

Aditya Arun Kumar Transitions to Non-Executive Role

Aditya Arun Kumar has been redesignated as Non-Executive Director (Non-Independent) of the company with effect from June 1, 2026, subject to shareholders' approval. Aditya tendered his resignation from the executive role on May 13, 2026, citing the promoters' stated intention to further professionalize the management of Strides. He holds a Bachelor's Degree in Biomedical Sciences from Newcastle University and a Master of Research in Biophysics from King's College, London, and has over 13 years of experience in the pharmaceutical industry. Aditya commenced his career with Strides as a Management Trainee and has since held multiple roles across Strides and the promoter Family Office. He played a significant role in expanding and strengthening the partnered and B2B business verticals, having led the B2B business since 2022. Consequently, Aditya will cease to hold office as Executive Director – Business Development and as KMP with effect from end of business hours of May 31, 2026.

Nandini Matiyani and Ariff Khan Nominated as SMP

Nandini Matiyani has been redesignated as Group Chief Human Resource Officer (CHRO) and nominated as Senior Management Personnel effective June 1, 2026. She has been part of Strides since December 2025 and brings over two decades of experience in human resources. Prior to joining Strides, she held senior HR leadership roles at RateGain, Wipro, and OnMobile Global.

Ariff Khan, Executive VP – Manufacturing Operations, has been nominated as SMP effective June 1, 2026, consequent to Ramaraju PVS's elevation to the Board. Ariff has been associated with Strides since May 2024 and currently heads manufacturing operations across India. He holds a Master's degree in Pharmacy and brings over 26 years of experience in the pharmaceutical sector.

Updated Board and KMP Composition

Following these changes, the updated Board of Directors of Strides Pharma Science effective June 1, 2026 comprises the following members:

The updated KMP list effective June 1, 2026 includes Badree Komandur (Managing Director & Group CEO), Venkata Seetharama Raju Pakalapati (Executive Director), Vikesh Kumar (Group CFO), and Manjula Ramamurthy (Company Secretary & Compliance Officer).

Strides Pharma Science Limited has informed the stock exchanges that the audio recording of its earnings call for investors and analysts, held on Monday, May 18, 2026, is now available on the company's website. The call was conducted at 17:00 hrs IST to discuss the audited financial results for the quarter and financial year ended March 31, 2026. The disclosure was made pursuant to Regulation 46 and Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Earnings Call Details

The earnings call was held as scheduled and brought together investors and analysts to review the company's audited financial performance for the quarter and financial year ended March 31, 2026. The audio recording has been made accessible on the company's official website under the Quarterly Financial Results section. The key details of the event are summarised below:

Regulatory Communication

The intimation was formally communicated to both BSE Limited and the National Stock Exchange of India Limited. The communication was signed by Manjula Ramamurthy, Company Secretary & Compliance Officer (ICSI Membership No. A30515), on May 18, 2026. Strides Pharma Science's registered office is located at 'Cyber One', Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India, and its corporate office is at Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India.